Professor Georgina Long makes history as the first woman and first Australian to lead the Society for Melanoma Research

Professor Georgina Long makes history as the first woman and first Australian to lead the Society for Melanoma Research

26 October 2018

In a double world-first, Co-Medical Director of Melanoma Institute Australia, Professor Georgina Long, is the first woman and the first Australian to be President of the prestigious Society for Melanoma Research (SMR).

Professor Long has been inducted as SMR President at the 15th International Congress of the Society for Melanoma Research in Manchester, England.

Her election as President is testament to her international standing as one of the world’ pre-eminent melanoma clinicians and researchers, with her ground-breaking clinical trials tripling life expectancy for some advanced melanoma patients, and essentially curing others.

‘It is a great honour to represent and lead this prestigious research society,’ Professor Long said. ‘Its members are leaders in the field of cancer research, and it was this group of researchers that lead the penicillin moment in cancer-therapy with immune checkpoint inhibitors.

‘I am excited and humbled to receive the baton from Professor Keith Flaherty who has served as President for the last two years.’

Fellow Co-Medical Director of Melanoma Institute Australia, Professor Richard Scolyer, said the history-making accolade is well deserved.

‘Professor Long has changed the face of melanoma treatment around the world and many thousands of people are alive today thanks to her intellect, determination and passion,’ Professor Scolyer said.

‘To be the first Australian and the first woman elected as SMR President shows Professor Long’s stellar international reputation. It is thanks to her research and global thought leadership that the world is now realistically looking towards advanced melanoma one day becoming a chronic disease rather than a terminal one.’

Founded in 2004, the US-based Society for Melanoma Research is the world’s largest association of melanoma researchers and scientists. Its multidisciplinary approach promotes international collaboration aimed at facilitating innovative solutions to the challenges faced by melanoma clinicians and researchers across the globe.

Only three years ago, Professor Long was the recipient of the Young Investigators Award at SMR, presented to an independent researcher in the early stages of their career who has surpassed all expectations in their contributions to melanoma research.

Professor Long leads the clinical trials team and laboratory at MIA, with a focus on targeted therapy and immune-oncology in melanoma. She is Principal Investigator on Phase I, II and III trials in adjuvant and metastatic melanoma, and is the Chief Investigator on research funded by the NHMRC that looks at tissue biomarker correlates of systemic therapy sensitivity and resistance.

Professor Long has authored over 200 publications in melanoma clinical and translational research, including in high-impact journals such as the New England Journal of Medicine and The Lancet. She has presented at hundreds of international conferences.

In addition to her joint medical leadership of Melanoma Institute Australia, Professor Long is Chair of Melanoma Medical Oncology and Translational Research at Royal North Shore Hospital, The University of Sydney. She is also the medical oncology lead for the Australian Melanoma Management Guidelines Committee, is on the editorial boards of several high-impact journals, and is a member of the Melanoma Expert Panel for AJCC Cancer Staging System 8th edition.

Amongst her numerous awards include the prestigious Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research in 2016, and last year the translational research team led by Professors Long and Scolyer received the award for Excellence in Translational Cancer Research at the NSW Premier’s Awards for Outstanding Cancer Research.

‘Professor Long’s election as President of arguably the world’s most prestigious association fostering international collaboration between leading melanoma researchers and clinicians is a proud moment for us all here at Melanoma Institute Australia,’ said Matthew Browne, CEO.

‘Hardly a week goes by without a melanoma patient or their family expressing their gratitude for Professor Long’s ground-breaking research and clinical trials which have afforded them or their loved ones valuable extra time, and in many cases, a new chance at life.

‘She is a true role model for all young Australians, particularly young women, who may be working towards a career in science and medicine,’ he said.

Best practice guidelines for melanoma care go digital
28 Oct 2016

Best practice guidelines for melanoma care go digital

Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.

Awards and honours for our talented researchers
26 Oct 2016

Awards and honours for our talented researchers

Congratulations are in order for two of our talented researchers.

5 Minutes With Prof Richard Scolyer
21 Oct 2016

5 Minutes With Prof Richard Scolyer

Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on. 

Research spotlight: High Risk Clinic
10 Oct 2016

Research spotlight: High Risk Clinic

Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.

Learning from the best in the world
05 Oct 2016

Learning from the best in the world

A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.

Uniting the world for a cure
30 Sep 2016

Uniting the world for a cure

MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients

A Day in the Life of... Michelle Peranec
30 Sep 2016

A Day in the Life of... Michelle Peranec

Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.

Wildfire Award helps ignite new melanoma research
08 Sep 2016

Wildfire Award helps ignite new melanoma research

Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.

Opinion: Fighting the Resistance
25 Aug 2016

Opinion: Fighting the Resistance

Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.

5 Minutes With A/Prof Jennifer Wargo
11 Aug 2016

5 Minutes With A/Prof Jennifer Wargo

A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.

Dr James Wilmott awarded for outstanding cancer research
06 Aug 2016

Dr James Wilmott awarded for outstanding cancer research

Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.

Community invests in MIA's new trial
19 Jul 2016

Community invests in MIA's new trial

The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial. 

New trial giving options
18 Jul 2016

New trial giving options

We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.

Melanoma research summary from ASCO
07 Jul 2016

Melanoma research summary from ASCO

Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.

Our Privacy Policy has been updated
06 Jul 2016

Updated privacy policy

We value your privacy and want you to be familiar with how we collect, use and disclose your information.

Can cognitive technology assist with melanoma identification?
29 Jun 2016

Can cognitive technology assist with melanoma identification?

Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology.

'4 Questions With...' Series
24 Jun 2016

'4 Questions With...' Series

CEO Carole Renouf chats to senior clinicians and researchers as part of our "4 Questions With..." short video series. 

Stop the Spread campaign shortlisted
22 Jun 2016

Stop the Spread campaign shortlisted

MIA's 'Stop the Spread' campaign has been shortlisted in the 2016 Cannes Lions International Festival of Creativity.

Merkel Cell Carcinoma: the hidden skin cancer
22 Jun 2016

Merkel Cell Carcinoma: the hidden skin cancer

Merkel cell carcinoma is a rare but aggressive skin cancer that is often hard to diagnose.

A meeting of the minds
02 Jun 2016

A meeting of the minds

MIA's doctors are converging on Chicago this week along with 40,000 delegates from around the globe at the biggest oncology conference in the world.